Eiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a report issued on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The firm has a market capitalization of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83. The company has a 50 day moving average of $4.85 and a 200-day moving average of $7.03. Eiger BioPharmaceuticals has a 52 week low of $1.10 and a 52 week high of $43.35.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.